NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,207.13 +444.10 (+2.50%) CRUDE OIL
79.15 +0.20 (+0.25%) GOLD FUTURES
2,313.70 +4.10 (+0.18%) DOW
38,225.66 +322.37 (+0.85%) Bitcoin GBP
47,384.48 +1,220.53 (+2.64%)
AnaptysBio, Inc. (AN6.F)
| Previous close | 22.80 |
| Open | 24.00 |
| Bid | 24.60 x 0 |
| Ask | 25.00 x 0 |
| Day's range | 23.60 - 24.80 |
| 52-week range | 12.30 - 24.80 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 709.332M |
| Beta (5Y monthly) | -0.29 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.67 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 35.33 |
ZacksAnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
AnaptysBio (ANAB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksAnaptysBio (ANAB) Soars 14.3%: Is Further Upside Left in the Stock?
AnaptysBio (ANAB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
PR NewswireActym Therapeutics Appoints Thomas Smart as CEO
Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer. With 25 years of experience in senior management and executive roles as well as Board of Directors positions across the biopharmaceutical industry, Mr. Smart brings a significant track record in leading organizations through value-building transitions. His breadth of expertise will be highly beneficial to Actym as it prepares to enter clinical eval
